CHICAGO — Patients with psoriatic arthritis (PsA) receiving GLP-1 receptor agonists (GLP-1s) had lower risks for death and experiencing major adverse cardiac events than patients with PsA not taking ...
Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.
DENVER — Adding the weight-loss drug tirzepatide to the biologic ixekizumab significantly improved joint and skin outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results